Abstract
To the Editor: We conducted the first Belgian multicentric observational study that investigated the long-term (up to week 88) effectiveness and tolerability of guselkumab in the treatment of plaque-type psoriasis. Guselkumab (Tremfya, Janssen Biotech, Inc) is indicated for the treatment of moderate to severe plaque psoriasis or active psoriatic arthritis and binds selectively to interleukin 23p19.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
